DCOY · Decoy Therapeutics Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. Based on Decoy's expected cash requirements, Decoy believes that there is substantial doubt that its existing cash and cash equivalents, will be sufficient to fund its operations through one year from the financial statements' issuance date.”View the 10-Q filed May 8, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent on equity repurchases (common and preferred combined, as reported) per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2021-02-05 | — | — | 2025-09-30 | — | 10-Q , filed 2025-11-14 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2019-12-31 | $0 | 10-K, filed 2020-03-23 |
| 2018-12-31 | $615,014 | 10-K, filed 2020-03-23 |